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Post-licensure  real world  evaluation  of vaccine  implementation  is important  for establishing  evidence  of
vaccine effectiveness  (VE)  and  programme  impact,  including  indirect  effects.  Large  cohort  studies  offer
an important  epidemiological  approach  for evaluating  VE,  but  have  inherent  methodological  challenges.
Since March  2012,  we  have  conducted  an  open  prospective  cohort  study  in  two  sites  in  rural
Malawi to evaluate  the  post-introduction  effectiveness  of  13-valent  pneumococcal  conjugate  vaccine
(PCV13)  against  all-cause  post-neonatal  infant  mortality  and  monovalent  rotavirus  vaccine  (RV1)  against
diarrhoea-related  post-neonatal  infant  mortality.  Our  study  sites  cover  a population  of 500,000,  with  a
baseline  post-neonatal  infant  mortality  of  25 per  1000  live  births.
We conducted  a methodological  review  of  cohort  studies  for vaccine  effectiveness  in  a  developing
country  setting,  applied  to  our  study  context.  Based  on  published  literature,  we  outline  key  consider-
ations  when  deﬁning  the  denominator  (study  population),  exposure  (vaccination  status)  and  outcome
ascertainment  (mortality  and  cause  of  death)  of such  studies.  We  assess  various  deﬁnitions  in these  three
domains,  in terms  of their  impact  on  power,  effect  size  and  potential  biases  and  their  direction,  using  our
cohort  study  for  illustration.  Based  on  this  iterative  process,  we  discuss  the pros  and  cons  of  our  ﬁnal  per-
protocol  analysis  plan.  Since  no  single  set  of  deﬁnitions  or  analytical  approach  accounts  for  all  possible
biases,  we  propose  sensitivity  analyses  to interrogate  our  assumptions  and  methodological  decisions.In the  poorest  regions  of  the  world  where  routine  vital  birth  and  death  surveillance  are  frequently
unavailable  and  the  burden  of  disease  and death  is  greatest  We  conclude  that  provided  the  balance
between  deﬁnitions  and their  overall  assumed  impact  on estimated  VE  are  acknowledged,  such  large
scale  real-world  cohort  studies  can  provide  crucial  information  to policymakers  by  providing  robust  and
compelling  evidence  of  total  beneﬁts  of  newly  introduced  vaccines  on reducing  child mortality.
ublis©  2015  The  Authors.  P
. BackgroundThe 13-valent pneumococcal conjugate vaccine (PCV13) and
onovalent rotavirus vaccine (RV1) were introduced to the routine
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infant vaccine schedule in Malawi in November 2011 and October
2012, respectively. Evidence of their effectiveness and population
impact on mortality in sub-Saharan Africa is needed, particularly
where HIV, malaria and malnutrition are prevalent. To date several
modelling studies have projected their impact in this setting, but
observational data on their empirically observed mortality impact,
which exist elsewhere, are lacking for sub-Saharan Africa [1–7].
Pre-licensure vaccine efﬁcacy is determined through placebo-
controlled double-blind randomized trials [8]. Post-licensure
studies are needed to determine vaccine effectiveness (VE) and
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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opulation impact, including indirect effects (herd immunity and
hanges in transmission dynamics at the population level) in the
real world’ setting. Effectiveness is often assumed to be lower than
fﬁcacy, since cold chain implementation and stock administration
re frequently suboptimal compared with strict trial conditions [9].
easures of effectiveness are by nature observational and therefore
ulnerable to confounding and bias, namely being unable to fully
ccount for the individual decision to seek vaccination [10]. How-
ver, they may  provide a more generalizable result, and because
f size and exclusions, it is difﬁcult for licensure trials to include
n assessment of herd protection (unless randomized by cluster), a
ey beneﬁt of many infant vaccines. Therefore, post-licensure effec-
iveness evaluations are crucial for policy makers to assess vaccine
oll-out, highlight issues in programme implementation and deter-
ine total impact of direct and indirect effects at population level
8,11].
Several observational methods exist for evaluating VE: serolog-
cal (using correlates of protection), ecological (population-level
urveillance, including analysis of electronic medical records),
ohort and case-control studies [8,12–17]. Each method has biases,
dvantages and disadvantages in practice, and variable utility in
ssessing potential non-speciﬁc vaccine beneﬁts or risks. Each
ethod also addresses slightly different questions about vaccine
ffectiveness and the preferred design may  be context dependent;
or example, a case-control design where the disease is extremely
are; or a cohort when investigating multiple outcomes for one
xposure. Using a carefully selected and complementary combi-
ation of observational methods affords a more comprehensive
nderstanding of vaccine impact, effectiveness and changing epi-
emiology of the target disease.
Cohort studies are resource intensive, requiring large sample
izes if events (such as death) are uncommon or if absolute effect
izes are small. As under-5 mortality rates are declining globally
18], cohorts with mortality end-points will become increasingly
hallenging. However, they avoid biases arising from selecting
ppropriate controls and censoring by survivorship to which other
bservational methods for estimating VE are more susceptible [19].
hree deﬁnitions are key to the design of a cohort study: the denom-
nator (deﬁning the study population), exposure ascertainment
with respect to vaccination status) and outcome ascertainment
mortality and cause of death) [20]. With these key parameters,
he standard approach to analysis would be a comparison of the
azard of death or survival by vaccination status adjusted for key
onfounders.
In this paper, we aim to discuss key methodological challenges
nherent to cohort designs focusing speciﬁcally on these three
omains and apply them to our study setting to clearly illustrate
ractical considerations in establishing an a priori ‘per-protocol’
nd sensitivity analysis plan. These analyses aim to give VE esti-
ates, acknowledging that in complex ﬁeld environments with
nmeasured confounding (such as bias in the decision to receive
accines or not), causality is difﬁcult to assign.
. Methods
We  conducted a methodological review of cohort study design
or evaluating vaccine effectiveness in a developing country setting.
e searched Web  of Science and PubMed using the follow-
ng terms: method* AND/OR cohort, AND vaccine effectiveness
ND/OR survival analysis, and included secondary references and
ighly-cited papers in the ﬁeld. Our subsequent discussion focuses
n the key challenges and considerations highlighted in the litera-
ure and use our ﬁeld setting to illustrate key considerations. Based
n this iterative process, we develop and present our primary and
ensitivity analysis plan.Fig. 1. Schematic of study recruitment, follow up and deﬁnitions.
3. Cohort recruitment
3.1. Setting
A prospective cohort study is ongoing at two sites in Malawi:
Mchinji district in the central region, and the Karonga demographic
surveillance site (DSS) in northern Malawi [21,22]. Since 1 March
2012, we  have conducted an open prospective cohort study in Mch-
inji district, which has a population of 465,000. The DSS site in
Karonga has been running since 2002, covering a population of
35,000. Both sites are rural and the main occupation is subsistence
farming [23]. Around 20% of the population is aged under 5 years
and crude birth rate is approximately 40/1000 person years. Under-
5 mortality has declined by 18 deaths/1000 live births over a 5 year
period to a rate of 71/1000 in 2013 [24], with much of this effect
seen in post-neonatal infants. The primary research questions for
this cohort study are:
- What is the effectiveness of three doses of PCV13 against all-cause
mortality in infants?
- What is the effectiveness of two doses of RV1 against diarrhoea-
speciﬁc mortality in infants?
This study is being conducted alongside case-control studies
with a range of morbidity and laboratory conﬁrmed endpoints, to
provide comprehensive data on vaccine effectiveness and impact
in different population settings in Malawi [21].
3.2. Data collection
The DSS methods for Karonga have been published in detail
previously [22]. The Mchinji surveillance site uses similar, but less
resource-intensive methods, to the Karonga site [21]. Brieﬂy, both
systems are based on networks of volunteer village-level key infor-
mants who  report monthly on births and deaths (Fig. 1). Selecting
appropriate key informants was done with extensive community
engagement to ensure they were acceptable to the community
since without this support accurate reporting of events would be
unlikely. In Mchinji infants are followed up by ﬁeld enumera-
tors with a home visit at 4 months and 1 year of age to capture
vaccine status and conﬁrm survival. At these visits, a one-page
questionnaire is administered, collecting information on infant and
mother survival, vaccine status (from documented health record or
parental recall when documentation is unavailable), maternal edu-
cation, household composition and assets. The large population size
and human resource constraints limited the length of the question-
naire in the Mchinji setting. In the Karonga DSS, a rolling population
demographic census visits all households in the entire population
4750 C. King et al. / Vaccine 33 (2015) 4748–4755
Table 1
Summary of advantages and disadvantages of different target populations in a cohort study of vaccine effectiveness, using PCV13 as an example.
Age of inclusion Target group Advantages Disadvantages Direction of Bias Comment
4–52 weeks Post-neonatal infants High recruitment of
deceased infants
Includes vaccine
ineligible infants
Overestimated VE Includes infants who have not had
the opportunity to be vaccinated
(non-outstanding), therefore
leading to higher vaccine
effectivenessa
6–52 weeks Any dose age-eligible
infants
Relatively high
recruitment of
deceased infants
High proportion of
unvaccinated infants
Overestimated VE
14–52  weeks Fully vaccinated
infants:
age-eligible for ﬁnal
dose
Relatively high
recruitment of
deceased infants
Low vaccine coverage
and protection
Unclear direction of
bias
May  decrease VE as vaccinated but
unprotected infants are considered
vaccinated. Or may increase VE as
untimely vaccination leads to more
unvaccinated infants being
included
16–52  weeks within 2 weeks of
recommended week as
a  strict cut-off
Per guidelines
deﬁnition of
vaccination
Low vaccine coverage Unclear direction of
bias
18–52  weeks within the
recommended month
as a moderate cut-off
Moderately high
vaccine coverage
Low recruitment of
deceased infants
Inconclusive VE Using later cut-offs will decrease
recruitment of deceased infants,
reducing the power
20–52  weeks within 6 weeks of the
recommended month
as a moderate cut-off
Moderately high
vaccine coverage
Low recruitment of
deceased infants
Inconclusive VE
26–52  weeks by 6 months of age as a
liberal cut-off
High vaccine coverage Low recruitment of
deceased infants
Inconclusive VE
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DCV13: 13 valent pneumococcal conjugate vaccine; VE: vaccine effectiveness.
a In this scenario, infants who were not age-eligible for all doses but died before
ither  unvaccinated or partially vaccinated, increasing the apparent vaccine effectiv
ver the course of a year, survivorship and vaccine status are con-
rmed and extensive socio-economic questionnaires completed.
n both sites, households with infant deaths are visited and a ver-
al autopsy (VA) questionnaire administered by senior research
fﬁcers. Identical socio-economic and vaccine status questions are
sked for surviving and deceased infants. The inclusion of two study
ites, in addition to increasing sample size, allows one to act as an
ndependent quality check on the other.
.3. Sample size
For PCV13, we calculated the sample size based on the base-
ine assumption of a post-neonatal infant mortality of 25/1000 live
irths (reported by the Karonga DSS for 2011/2012), three-dose
accine coverage of 75% and 12% loss to follow-up. Assuming vac-
ine can only lower and not increase mortality, we  used a one-sided
og-rank test to calculate that we require 34,848 infants surviv-
ng to 1 year and 729 deaths amongst post-neonatal infants (aged
28 days) to have 80% power to detect PCV13 vaccine effective-
ess of ≥20% against all-cause mortality. Pneumonia, meningitis
nd sepsis account for 40% of deaths in post-neonatal infants, there-
ore ≥20% effectiveness was chosen as a modest estimate of effect
ize.
For RV1, our pre-RV1 introduction surveillance observed post-
eonatal infant diarrhoea-related mortality of 6/1000 live births,
nd at 75% two-dose coverage and 12% loss to follow-up we require
3,668 infants and 210 diarrhoea deaths for 80% power to detect
V1 vaccine effectiveness of 36% against diarrhoea-related deaths.
s we accrue more accurate information on cause-speciﬁc mortal-
ty and vaccine coverage, our targets may  need revision. To date
May 2015), we have recruited 50,000 PCV13 eligible infants and
5,000 infants eligible for RV1.
. Denominator
When deﬁning the cohort sampling frame (”target population”),
esign decisions need to be made in terms of the age-eligibility and
atchment population. Several age-eligibility options are possible,
ach with advantages and disadvantages with any cohort deﬁni-
ion requiring a trade-off between power and estimated effect.
elayed timeliness in vaccine uptake means that inclusion from a had the opportunity to receive all doses would still be included in the analysis as
.
younger age increases the number of partially vaccinated deceased
infants, since they die before having the chance to receive all
doses; this may  overestimate VE as there are more deaths are in
unvaccinated infants. However, using more liberal time cut-offs to
allow for higher vaccine coverage would result in lower power (i.e.
fewer recruited deaths) and misses a critical time period for deaths.
We  opted to include infants surviving to 14 weeks for the PCV13
analysis and 10 weeks for the RV1 analysis, following them to sur-
vival at 1 year, death or migration (censoring) before 52 weeks
(Table 1). This deﬁnition maximizes cohort size, excluding only
vaccine-age-ineligible infants. We  will conduct sensitivity analyses
using 6-week (earliest age-eligibility for vaccination) and 6-month
(complete vaccination, allowing for poor timeliness) survival inclu-
sion cut-offs, and 16 and 12 weeks for PCV13 and RV1, respectively
(allowing for immunogenicity of the ﬁnal dose).
We  deﬁned the eligible catchment population as all infants ‘born
to an established household within the geographical region under
surveillance’ (i.e. Mchinji District and the Karonga DSS). An ‘estab-
lished household’ is deﬁned as one which has been reported by
village informants to have been present for at least 2 months at the
time of the birth event. This seemingly straightforward demarca-
tion is in reality more complex. For example, Mchinji district has
two international borders, numerous commercial farming estates
and neighbours the capital city district of Lilongwe which makes
migration, resulting from seasonal harvesting and urbanization,
challenging to monitor. Intricate situations (e.g. a complicated
delivery being sent to a tertiary referral centre outside the district)
may  be misrepresented under this system, but such events are rare
and unlikely to alter VE estimate substantially.
5. Exposure (vaccine status)
The exposure of interest is vaccination. Vaccination status can
be ascertained from several sources, including care-giver report
and documented health record, and the choice of source requires a
trade-off between potential bias and power. Two  key assumptions
in the analysis of observational effectiveness studies are that there
are no unmeasured systematic differences between the exposed
and unexposed and that there is no differential exposure ascertain-
ment by outcome [12]. These assumptions are likely to be violated,
as outlined below.
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[35,36]; in our data only 10% of infants received all recommended
vaccines (BCG, four doses Polio, three doses Pentavalent and PCV13
and two doses RV1) within a fortnight of the schedule. Using a strict
deﬁnition of timeliness would impact study recruitment (Fig. 2)
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.1. Unmeasured differences between exposure groups
Vaccinated infants may  differ in other health and social meas-
res from unvaccinated infants. In our setting, households with
ower incomes are more likely to have limited access to clean
ater and sanitation and by implication higher propensity to
isease. When compounded by fewer available funds to seek
are (and therefore vaccination, as has been shown in Karonga
nd elsewhere) [25–28] could result in higher mortality. Notably,
imited care seeking is also a reason why community household
urveillance is important, since such cases would be missed by
ealthcare-based surveillance. With the limited socio-economic
nformation, we collect adequately accounting for the intricacies of
he relationship between socio-economic factors, health status and
ealth seeking behaviors is difﬁcult. For these same reasons, knowl-
dge of the birth and determining the vaccine status of infants
ho remain unvaccinated may  be more challenging than ascer-
aining those who are subsequently vaccinated. Failure to identify
nvaccinated infants would overestimate vaccine coverage among
urviving infants resulting is a strongly biased increase in apparent
accine effectiveness.
.2. Exposure ascertainment by outcome
Many developing countries have three potential sources for
scertaining vaccine exposure: health passports, vaccine clinic reg-
sters and parental recall. In Malawi, children are issued a free
health passport’ at their ﬁrst encounter with the healthcare sys-
em, in which vaccinations are recorded. All clinics that distribute
accines are required to document delivered antigens in gov-
rnment implemented ‘Under-1 registers’, including information
n each child’s name, date of birth and village. At ﬁrst vaccina-
ion, a non-unique sequential identiﬁer is transcribed onto the
ealth passport and is recorded at subsequent visits; in practice
inkage across visits is poor and linkage between facilities impos-
ible. The availability of health passports is associated with both
xposure (e.g. infants with no health passport are less likely to
ave had any contact with the health system and therefore vac-
inations) and outcome as the health passport is often buried
ith deceased infants. This violates the assumption that exposure
scertainment will not differ between deceased and surviving chil-
ren.
Although relying on documented evidence of vaccination to
etermine exposure has a high positive predictive value (PPV)
or true vaccination status, it may  have poor negative predic-
ive value (NPV). Missing documentation of vaccine receipt in
urviving children (misclassiﬁcation bias), would result in appar-
nt decreased vaccine effectiveness as those truly vaccinated are
ecorded as unvaccinated. In deceased infants, misclassiﬁcation
s non-exposed in those vaccinated would bias toward apparent
ncreased vaccine effectiveness [8]. As a quality control activ-
ty, we collect data on vaccine discrepancy between care-giver
eports and health passports immediately following vaccination.
ur data show 4% misclassiﬁcation of vaccines, with 2% undoc-
mented and 2% documented when not given, using care-giver
eport as the reference standard. Since the misclassiﬁcation is ran-
omly bi-directional, poor reporting is unlikely to introduce bias
hen documentation is available.
Parental recall is generally considered less reliable than doc-
mented evidence, as care-givers may  over-report vaccination to
eet expectations of health researchers or under-report if poorly
ecalled or parents hope their child will receive beneﬁt of another
ose. Evidence for the direction of such bias is limited; though a
tudy from Kenya found parental recall underestimated vaccine
overage compared with documented status [29]. Classifying chil-
ren according to parental report in the absence of documentation(2015) 4748–4755 4751
mitigates the biases of relying solely on documented evidence,
which is less frequently available for deceased infants [30], but on
the other hand may  reduce the NPV. We  will use combined data
from the three sources to classify exposure ascertainment, apply-
ing a data reliability hierarchy to achieve the best balance between
PPV and NPV (see Supplementary Material 1).
5.3. Multiple doses
Vaccination status can be deﬁned as:Unvaccinated–received no
doses; fully vaccinated–received all scheduled doses; partially vac-
cinated.
a. Non-outstanding: received at least one scheduled dose and not
yet age-eligible for more.
b. Outstanding: received at least one scheduled dose, but age-
eligible for further doses.
Including partially vaccinated infants into the vaccinated group
could underestimate effectiveness if immune protection is partial.
Including such infants in the unvaccinated group may  result in chil-
dren with partial protection being considered unvaccinated, again
lowering estimates of vaccine effectiveness [8]. We  deﬁne exposure
based on doses received keeping partially vaccinated infants in the
analysis as a discrete category; however our primary analysis will
only include outstanding partially vaccinated infants.
Not distinguishing between outstanding and non-outstanding
partially vaccinated infants could introduce bias in complex ways.
Outstanding children are older and their delayed vaccination may
be associated with other risk factors for poor outcome (such as
poor health seeking behaviors); contrarily, an older living cohort
introduces a survivor bias. By deﬁning our cohort as infants sur-
viving to age-eligibility for the ﬁnal dose, we will not be including
non-outstanding partially vaccinated infants. Sensitivity analyses
using older and younger age cut-offs for inclusion will allow us to
investigate further the effect of partially vaccinated infants.
5.4. Deﬁning timeliness
Published timeliness deﬁnitions vary from strict (vaccination up
to 14 days after recommendation), to lenient (receipt of vaccine up
to 2 months delayed) [20,31–34]. Delayed vaccination is common4 6 10 14 18 22 26 30 34 38 42 46 50
Age (we eks)
Fig. 2. Vaccine timeliness and age at death in post-neonatal infants–example of
cohort deﬁnition impacts on outcome and exposure.
4752 C. King et al. / Vaccine 33 
Box 1: Definition of vaccine timeliness.
We will use the following deﬁnition for deﬁning timely vaccine
receipt for PCV13 (3 doses) and RV1 (2 doses) [44]:
- Dose 1 (6 weeks) received between 4 weeks and 2 months.
- Dose 2 (10 weeks) received between 8 weeks and 4 months.
- Dose 3 (14 weeks) received between 12 weeks and 6 months.
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sWe  will also examine actual timeliness as a continuous covari-
ate in sensitivity analysis
nd may  introduce a bias as the low percentage of children who
eceive their vaccines according to the strict schedule may  dif-
er from the general population. On the other hand, including
nfants with a long delay may  bias toward lower effectiveness.
he timeliness deﬁnition is a trade-off between power and effect,
trict deﬁnitions reducing power and lenient deﬁnitions reducing
etectable effect. In the primary analysis, we will include timeliness
f vaccine receipt as a covariate in the model, using the deﬁnition
n Box 1 [35].
. Outcome
Two key issues relating to outcome are ascertainment and deﬁ-
ition, especially important for cause-speciﬁc mortality. Our study
utcomes for PCV13 and RV1, respectively, are all-cause mortal-
ty in infants aged 14−52 weeks and diarrhoea-related mortality in
nfants 10−52 weeks.
.1. Outcome ascertainment
To minimize differential censoring and misclassiﬁcation, effort
o ascertain outcomes should be equal in both outcome groups.
isclassiﬁcation of deaths can occur for several reasons: inaccurate
ge at death, misunderstanding of death deﬁnitions, and unreliable
eporting (e.g. relying on hearsay). Cultural barriers exist to openly
iscussing death in Malawi (especially among neonates, while in
ther cultures there may  be a gender bias), leading to misclas-
iﬁcation in reporting. Since death is uncommon more intensive
esources are required for ascertaining and verifying death than
urvival. Under-ascertainment of deaths reduces both power and
pparent effectiveness, as does misclassifying survivors as deaths.
e conduct VA household visits on all under-ﬁve deaths, including
tillbirths, to mitigate misclassiﬁcation bias.
.2. Cause-speciﬁc deﬁnitions
Like many developing countries [37], Malawi has no vital regis-
ration or death certiﬁcation system outside of the hospital setting,
herefore we use the WHO  2012 VA tool to collect data on signs
nd symptoms preceding death [38]. Interpretation of such data is
he subject of vigorous debate [39]. Three options exist for analy-
is of verbal autopsies based on the WHO  VA questions: physician
eview, custom-deﬁned algorithm or standardized models such as
nterVA (www.interva.net) or InSilicoVA (arXiv:1411.3042). Physi-
ian review is resource intensive and has poor standardization,
hile automated methods are highly repeatable [39–42]. In the
bsence of a gold-standard, validity of cause-speciﬁc mortality
ttribution of any method is unknown.
Inherently non-speciﬁc, the all-cause mortality outcome for
CV13 lowers effect size, and our sample size calculation assumes
 modest 20% reduction in deaths. Since there may  be other
rivers for reductions in infant mortality (e.g. improved nutrition
tatus), the analysis would be confounded if these non-vaccine(2015) 4748–4755
reductions are directly associated with individual vaccine sta-
tus as well as mortality. However, we chose all-cause mortality
due to its important policy implications and because syndromes
commonly caused by Streptococcus pneumoniae (sepsis/meningitis,
pneumonia) may be clinically non-speciﬁc and caused by other
pathogens, leading to a more challenging outcome to capture accu-
rately or consistently. We  will conduct a sensitivity analysis for
PCV13 against sepsis/meningitis or pneumonia deaths as deﬁned
by standardized models, and anticipate VE will be higher for these
outcomes.
Compared with physician diagnosed diarrhoea-related mor-
tality, study-speciﬁc algorithms have high sensitivity but poor
speciﬁcity [43,44]. The latter may  lower apparent VE. This bias
arises from misclassifying non-diarrhoeal deaths as diarrhoeal or
having a lower prevalence of rotavirus amongst selected deaths
(e.g. during a cholera outbreak). Although false positives lower
apparent effectiveness, with prevalent infections like rotavirus, the
false positivity rate is lowered and the impact of the bias reduced
[30]. Standardized computer models have shown variable perfor-
mance when compared with physician review (likely a reﬂection
of ﬂaws in both techniques) [39–42]. We  have decided to use a
study-speciﬁc algorithm for diarrhoea-related mortality, and will
conduct sensitivity analyses with standardized models. The all-
cause mortality endpoint was  abandoned for RV1 since PCV13
had been introduced in the previous year, further lowering post-
neonatal infant mortality and resulting in unachievable power for
that endpoint.
7. Primary analysis of vaccine effectiveness
To calculate the vaccine effectiveness of PCV13 and RV1, we  will
use Cox proportional hazards modelling of survival to 1 year [45].
Other reasonable analytical approaches (e.g. Mantel−Haenszel
estimators, log−binomial regression, robust Poisson or negative
binomial regression [46–48]) do not account for differential cen-
soring. Cox modelling has two key assumptions: that censoring is
unrelated to the outcome and that the hazards are proportional
over time. For both assumptions, violations may occur in practice.
For example, itinerant agricultural laborers who  leave the dis-
trict for economic reasons may  have a lower socio-economic status,
which drives them to migrate, or harvesters who  temporarily reside
deep in the ﬁelds rather than at home may  have lower likeli-
hood of vaccination and independently higher mortality [26,49].
Therefore, if such families have higher infant mortality this vio-
lates the assumption that censoring is unrelated to outcome. The
assumption of proportionality may  also be violated as mortality
risk (outcome) is generally age-associated, as is vaccination (expo-
sure). Mortality in infants decreases with age while the likelihood of
being vaccinated increases with each month survived, so there may
be non-proportionality in outcomes between exposure groups over
time. Methods for testing proportionality (e.g. Schöenfeld residuals,
[50]) and mitigating its violations exist [51,52]. If we  ﬁnd the pro-
portionality assumption violated, we  will allow for time-varying
covariates [53].
7.1. Confounders and risk factors
Since both vaccine receipt and outcome may  be associated with
classical confounding, measuring and adjusting for these is criti-
cal. In a Swedish study, unadjusted inﬂuenza VE was 50% while
adjusted for confounders was 14% [54]; in our context, the magni-
tude and direction of bias are difﬁcult to predict. We will include
the following covariates in our primary analysis: socio-economic
status; other vaccine receipt, timeliness and distance to nearest
vaccination centre; mother’s survival and health centre catchment
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Box 2: Per-protocol analysis definition.
Denominator: Children surviving to age-eligibility for the ﬁnal
dose (14 weeks for PCV-13 and 10 weeks for RV1), who  were
born to a household that had been continuously present in the
geographical region under surveillance for at least 2 months
prior to the birth, according to the village key informant.
Exposure: Either of documented evidence or parental report of
vaccination status (assigned through a hierarchy algorithm),
as a discrete numerical variable for each scheduled dose.
Outcome: All-cause mortality in children surviving to age-
eligibility for the ﬁnal dose conﬁrmed by home visit (PCV13)C. King et al. / Vacci
as a ﬁxed variable). It is improbable that all confounders can
e accounted for and differential ascertainment of confounders
y exposure or outcome status is likely. For example, we  collect
id-upper arm circumference (MUAC), a proxy measure of nutri-
ional status in children and a good predictor of mortality [55];
ollecting MUAC for surviving children is done at follow-up, but this
s not possible for deceased children. In sensitivity analysis, we will
nvestigate unmeasured confounding using a method described by
roenwold et al. [56], which simulates unmeasured confounders
ased on substantive knowledge of its association with the outcome
nd exposure.
. Sensitivity analyses
The primary analysis of assessing individual vaccine status and
urvival adjusted for confounders and risk factors does not provide
nformation on vaccine impact and is unlikely to account for all
onfounders or drivers of individual decisions in vaccine uptake.
herefore, the use of sensitivity analyses is essential for exploring
ndirect effects, the role of unmeasured confounders and con-
rming the ﬁndings of the primary analysis to provide a more
omplete picture of vaccine effectiveness.
.1. Cluster-level analysis
Cluster-level analysis, either grouping by geographical region
r by time-periods, addresses programme impact [12]. We  will
egress mortality rates against vaccine coverage at a geographical
luster level adjusting for socio-economic measures. In choosing
he cluster deﬁnition (e.g. health centre catchment, community
ealth worker catchment, village), we aim to maximize cluster
umber while maintaining adequate cluster size and inter-cluster
eterogeneity. We  will also investigate random-effects models that
ncorporate both individual and cluster-level covariates, which
llow examination of cluster effects on individual mortality hazard.
.2. Competing risks
A key consideration in carrying out survival analysis for cause-
peciﬁc deaths is the issue of ‘competing risks’. A child dying of
neumonia cannot then die again of diarrhoea, and so is cen-
ored. Given the relatively high infant mortality rate in Malawi,
uch competing risks are an issue in the analysis of RV1 against
iarrhoea-speciﬁc mortality endpoint. Competing risks regression
ill be used to investigate this, and may  help explore synergistic
ffects of both vaccines [57].
.3. Quasi-experimental approaches
Quasi-experimental approaches are used to evaluate causal
nference from observational data, in an attempt to account for
he lack of randomization in treatment assignment and there-
ore potential missed confounders (resulting in endogeneity). Two
pproaches which may  be appropriate for vaccine effectiveness
sing cohort data are instrumental variables and propensity score
atching. Using instrumental variables, a method widely used
n econometrics, vaccine status would be replaced with a substi-
ute exposure variable which is independent of the unmeasured
onfounder, thus avoiding endogeneity [58,59]. As socio-economic
tatus may  differ by exposure [26] and by outcome, it can give rise to
 ‘self-selection bias’ whereby poor infants are both unvaccinated
nd die as a result of poverty, increasing apparent VE even after
djustment [49]. Using an instrumental variable could mitigate this
ias and address any issues in missing exposure status, by select-
ng a variable associated with vaccination status but independent
f socio-economic status. The challenge is selecting an appropriate(2015) 4748–4755 4753
instrumental variable. One possibility is vaccine stock availabil-
ity at local clinic level. However, this too may be associated with
socio-economic status of the catchment area, with clinics closer to
tarmac roads both more likely to have regular supplies and more
trade leading to higher socio-economic status of the surrounding
population. An obvious choice for an independent instrumental
variable is lacking in our situation, precluding the use of this
method.
Propensity score matching is a method which accounts for the
probability of receiving a treatment or intervention (i.e. vaccina-
tion) based on covariates to adjust the effectiveness model. This
method has been used previously in the analysis of observational
vaccine effectiveness studies [60,61], and could provide insight into
our assumptions about residual unaccounted confounding.
9. Conclusion
The evaluation of vaccine effectiveness against mortality using
cohort studies is complex and with globally declining mortal-
ity is becoming increasingly challenging as larger cohorts that
are subject to more confounding are required. It is imperative to
ensure that estimates of vaccine effectiveness are as valid and
accurate as possible despite the biases inherent in large-scale,
real-world observational studies. The complexities we have iden-
tiﬁed, such as differential vaccine ascertainment and lack of gold
standard cause of death information, are likely to challenge vac-
cine evaluations in other low-resource settings and our approach
to deﬁning the primary analysis is generalizable to similar study
designs.
While no single set of deﬁnitions or analytical approach can
address all possible biases and confounding, the careful a priori
consideration of denominator, exposure and outcome deﬁnitions
and of the analytical approaches can achieve a balanced ‘per-
protocol’ primary analysis (Box 2), which errs toward conservative
estimation of vaccine effectiveness. Sensitivity analyses are cru-
cial to interrogate assumptions and methodological decisions, and
to explore more subtle relationships between mortality, vaccine
exposure and inherent confounders. Only large-scale cohort stud-
ies can generate crucial evidence of total community mortality
reduction from vaccines in resource poor settings, which lack rou-
tine vital registration and where mortality burden is greatest. Such
studies provide essential information to policymakers by provid-
ing robust and compelling evidence of total beneﬁts of vaccines on
reducing mortality.OR pre-deﬁned clinical algorithm of diarrhoea-associated mor-
tality based on WHO  2012 VA questions in children surviving
to age eligibility for the ﬁnal dose (RV1).
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